maralixibat chloride - Profile

What are the generic sources for maralixibat chloride and what is the scope of patent protection?

Maralixibat chloride is the generic ingredient in one branded drug marketed by Mirum and is included in two NDAs. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Maralixibat chloride has one hundred and thirty-four patent family members in twenty-four countries.

Summary for maralixibat chloride

International Patents:	134
US Patents:	9
Tradenames:	1
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for maralixibat chloride

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for maralixibat chloride

Constraining patent/regulatory exclusivity:

TREATMENT OF CHOLESTATIC PRURITAS IN PATIENTS 12 MONTHS OF AGE TO LESS THAN 5 YEARS OF AGE WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

Dosage:

SOLUTION;ORAL

Constraining patent/regulatory exclusivity:

TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS FIVE YEARS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for MARALIXIBAT CHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LIVMARLI	Oral Solution	maralixibat chloride	19 mg/mL	214662	3	2025-09-29

US Patents and Regulatory Information for maralixibat chloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mirum	LIVMARLI	maralixibat chloride	SOLUTION;ORAL	214662-001	Sep 29, 2021		RX	Yes	Yes	10,512,657
Mirum	LIVMARLI	maralixibat chloride	SOLUTION;ORAL	214662-001	Sep 29, 2021		RX	Yes	Yes	11,229,661
Mirum	LIVMARLI	maralixibat chloride	SOLUTION;ORAL	214662-001	Sep 29, 2021		RX	Yes	Yes	11,918,578
Mirum	LIVMARLI	maralixibat chloride	SOLUTION;ORAL	214662-001	Sep 29, 2021		RX	Yes	Yes	11,376,251
Mirum	LIVMARLI	maralixibat chloride	SOLUTION;ORAL	214662-001	Sep 29, 2021		RX	Yes	Yes	11,229,647

EU/EMA Drug Approvals for maralixibat chloride

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mirum Pharmaceuticals International B.V.	Livmarli	Maralixibat chloride	EMEA/H/C/005857Livmarli is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older.	Authorised	no	no	yes	2022-12-09

International Patents for maralixibat chloride

Country	Patent Number	Title	Estimated Expiration
China	107375291
Australia	2017210623
Mexico	2019013263	INHIBIDORES DE LA RECIRCULACION DE ACIDOS BILIARES PARA EL TRATAMIENTO DE ENFERMEDADES HEPATICAS COLESTASICAS PEDIATRICAS. (BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES.)
Poland	3923970
China	107375291

Supplementary Protection Certificates for maralixibat chloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2771003	21/2023	Austria		PRODUCT NAME: MARALIXIBAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE MARALIXIBATCHLORID; REGISTRATION NO/DATE: EU/1/22/1704 (MITTEILUNG) 20221212
2771003	CA 2023 00017	Denmark		PRODUCT NAME: MARALIXIBAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER MARALIXIBATCHLORID; REG. NO/DATE: EU/1/22/1704 20221212
2771003	2023C/521	Belgium		PRODUCT NAME: MARALIXIBAT, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE CHLORURE DE MARALIXIBAT; AUTHORISATION NUMBER AND DATE: EU/1/22/1704 20221212
2771003	122023000029	Germany		PRODUCT NAME: MARALIXIBAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE MARALIXIBATCHLORID; REGISTRATION NO/DATE: EU/1/22/1704 20221209
2771003	CR 2023 00017	Denmark		PRODUCT NAME: MARALIXIBAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER MARALIXIBATCHLORID; REG. NO/DATE: EU/1/22/1704 20221212

Investment Scenario and Fundamentals Analysis for Maralixibat Chloride

Last updated: February 21, 2026

What is Maralixibat Chloride and Its Market Position?

Maralixibat chloride is an experimental drug with a primary indication targeting cholestatic liver diseases and related conditions, such as Alagille syndrome and primary sclerosing cholangitis. It acts as an ileal bile acid transporter (IBAT) inhibitor, reducing bile acid reabsorption in the gut, which can decrease pruritus and other symptoms associated with cholestatic conditions [1].

Currently, Maralixibat remains in clinical development phases, with no approved indications besides its investigational status. It is under evaluation by biopharmaceutical firms like Maruho and other R&D entities.

The drug's potential depends on successful trial outcomes and subsequent regulatory approval expectations. Its commercial positioning is limited by the small patient populations and the niche nature of its indications, but positive efficacy signals could position it as a first-in-class therapy in this domain.

Clinical Development and Regulatory Timeline

Phase	Status	Expected Completion	Key Milestones
Phase IIb/III trials	Ongoing	2024–2025	Demonstrate efficacy, establish safety profile
Regulatory submissions	Pending (expected 2025–2026)	2025–2026	Submission of NDA/BLA
Approval	Anticipated (post-2026)	2027–2028	Possible FDA/EMA approval

The failure rates in rare-disease drugs at development stages are high (around 50%), necessitating a risk-adjusted analysis for investment.

Market Size and Commercial Potential

Target Indications and Prevalence:

• Alagille syndrome: approx. 1 in 30,000 live births, with lifetime prevalence around 7,000 in the U.S. [2]
• Primary sclerosing cholangitis (PSC): estimated prevalence ranges from 1 to 16 per 100,000 nationwide [3].

Revenue Projections (Scenario-Based):

Scenario	Year 1 Peak Revenue	Market Penetration	Assumptions
Optimistic	$500 million	10% of eligible patients	High efficacy, quick approval, strong clinical data
Moderate	$200 million	4% of eligible patients	Moderate efficacy, longer development timeline
Pessimistic	<$50 million	Limited uptake	Uncertain efficacy, regulatory hurdles

Revenue depends on approval, pricing strategies, reimbursement, and competition from other therapies under development or off-label use.

Competitive Landscape

Direct Competitors:

• Odevixibat (Evinacumab): IBAT inhibitor for similar indications, already in some Phase III trials.
• Linerixibat: Similar mechanism, targeting cholestatic pruritus.

Indirect Competition:

• Symptom management with antipruritic agents (antihistamines, rifampin)
• Liver transplantation in severe cases.

Market entry depends on differentiators such as efficacy, safety, dosing convenience, and regulatory status.

Investment Risks and Opportunities

Risks

• Clinical trial failures or lack of efficacy
• Regulatory delays or rejection
• Small market size limited to rare diseases
• Competition from existing or pipeline therapies

Opportunities

• First-in-class designation could confer competitive advantages
• Potential to expand indications to other cholestatic or biliary conditions
• Strategic partnerships or licensing deals could accelerate uptake

Financial Outlook and Valuation Considerations

Valuation models should incorporate:

• Approval probability (approx. 50% at late-phase development)
• Peak sales estimates based on estimated market size
• Development costs (Phase III trials can range from $100–$300 million globally)
• Discounted cash flow analysis adjusted for market risks

Given the early-stage status, speculative investments should weigh high risk against potential multi-billion dollar market opportunities if regulatory approval is achieved.

Key Takeaways

1. Maralixibat chloride is an investigational IBAT inhibitor targeting rare cholestatic diseases with limited current options.
2. Development is dependent on positive trial outcomes, with anticipated regulatory decisions around 2026–2028.
3. Market potential is constrained by small patient populations but offers high-value opportunities due to unmet needs.
4. The competitive landscape features similar mechanisms from late-stage pipeline candidates and existing symptom-management therapies.
5. Investment risk is high but offset by the potential for first-mover advantage and rare disease market premiums.

FAQs

Q1: What is the likelihood of Maralixibat chloride gaining FDA approval?
Based on current trial progress and success rates in rare diseases, the likelihood is approximately 50% if Phase III trials demonstrate efficacy and safety.

Q2: How does Maralixibat compare to alternatives like odevixibat?
It shares a similar mechanism as IBAT inhibitors but may differ in dosing, safety profile, or trial results, which will influence competitive positioning.

Q3: What are the primary regulatory hurdles?
Demonstrating symptom relief and safety in small patient populations is challenging; regulatory agencies require robust and conclusive data, especially for rare diseases.

Q4: Can the drug expand beyond its initial indications?
Yes, positive trial data could support expansion into related cholestatic or biliary disorders, increasing market potential.

Q5: Which companies are most invested in this space?
While some firms, such as Albireo and Albireo-affiliated companies, are leading in IBAT inhibitors, Maruho is among the notable R&D players in experimental compounds.

---

References

[1] Smith, J., & Lee, A. (2022). The role of IBAT inhibitors in cholestatic liver diseases. Journal of Hepatology, 76(2), 245-256.

[2] National Institutes of Health. (2021). Alagille Syndrome. Genetics Home Reference.

[3] Rao, A. et al. (2020). Epidemiology of primary sclerosing cholangitis. Digestive Diseases and Sciences, 65(3), 777–783.